Vizamyl is a radioactive diagnostic agent indicated for Positron
Emission Tomography (PET) imaging of the brain to estimate β-amyloid
neuritic plaque density in adult patients with cognitive impairment who
are being evaluated for Alzheimer’s disease (AD) or other causes of
cognitive decline.